Autologous adipose-derived mesenchymal stem/stromal cells (Rigshospitalet)

N/A

Report date: 2023/01/12 15:28:58

Base Information

Drug NameAutologous adipose-derived mesenchymal stem/stromal cells (Rigshospitalet)

Drug Alias NameN/A

ClassificationCell and gene therapy > Cell therapy > Donor > AutologousCell and gene therapy > Cell therapy > Stem cell therapy > Mesenchymal stem cells therapyCell and gene therapy > Cell therapy > Source of cells > Adipose-derived

Mechanisms of ActionStem cell replacements

TargetsNot applicable

Therapy Area/IndicationsRadiation InjuriesLong Term Adverse EffectsRespiratory Tract Diseases +[5]

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryDenmark

CombinationsNo

Global Highest StatusPhase 2 Clinical

Highest Status in ChinaN/A

Originator CompaniesRigshospitalet

China Registration ClassN/A

Develop Information

Active CompaniesRigshospitalet

Inactive CompaniesN/A

Active IndicationsXerostomiaSjogren's Syndrome

Inactive IndicationsRadiation InjuriesLong Term Adverse EffectsRespiratory Tract Diseases

Other Information

ATC CodeN/A